• YAKHAK HOEJI
• /
• v.56 no.3
• /
• pp.186-190
• /
• 2012

Nuclear factor-${\kappa}B$ (NF-${\kappa}B$) has been considered as one of the major targets for therapeutic agents of diverse human diseases. In the previous studies, 6-hydroxy-7-methoxychroman-2-carboxylic acid N-phenylamide (KL-1156) and chroman-2-carboxylic acid N-(4-chlorophenyl)amide were identified as good inhibitors of NF-${\kappa}B$ activation. In this continuous study, we describe the synthesis and NF-${\kappa}B$ inhibitory activities of chroman derivatives containing N-heteroaryl groups for exploration of SAR (structure-activity relationship). In addition, inhibitory effects of cell proliferation are evaluated against human cancer cell lines (NCI-H23 and PC-3).

• YAKHAK HOEJI
• /
• v.57 no.6
• /
• pp.426-431
• /
• 2013

In our previous studies, 6-hydroxy-7-methoxychroman-2-carboxylic acid N-phenylamide (KL-1156) was identified as a good inhibitor of nuclear factor-${\kappa}B$ (NF-${\kappa}B$) activation. In continuation of our study, we describe the structure-activity relationship of chroman derivatives containing N-arylalkyl groups and their NF-${\kappa}B$ inhibitory activities. In addition, inhibitory effects of cell proliferation are evaluated against human cancer cell lines (NCI-H23 and PC-3). The most active compounds 3i and 3j contained diphenylethyl and diphenylpropyl side chain on amide nitrogen.

• YAKHAK HOEJI
• /
• v.50 no.5
• /
• pp.322-325
• /
• 2006

In the course of developing novel antioxidants, we synthesized four of 6-hydroxy-7-methoxy-4-oxochroman-2carboxylic acid dialkylamides (3a-d) $(13{\sim}18%)$ and four of 6-hydroxy-7-methoxychroman-2-carboxylic acid dialkylamides (4a-d) $(52{\sim}89%)$, incorporating the basic amine functionality. None of these compounds exhibited significant antioxidant activity possibly due to the hydrophilic character of the basic amine side chains.

• YAKHAK HOEJI
• /
• v.54 no.3
• /
• pp.200-204
• /
• 2010

Nuclear factor-${\kappa}B$ (NF-${\kappa}B$) plays critical roles in physiological and pathological processes such as immune function, cellular growth, homeostasis, apoptosis, and inflammation. As part of our ongoing efforts to develop novel NF-${\kappa}B$ inhibitory agents, we reported that KL-1156 (6-hydroxy-7-methoxychroman-2-carboxylic acid phenylamide) exhibited potent inhibitory activity of NF-${\kappa}B$. For further structure-activity relationship, a series of 7-aryloxy-chroman-2-carboxylamide derivatives were synthesized to explore their inhibitory activities of NF-${\kappa}B$.